SEE pharmaceutical market healthy in 2010

Stamov, Valentin; Pavlova, Iskra
January 2011
SEE Top 100;2011, p46
The article focuses on the condition of the pharmaceutical market in 2010 in Southeast Europe (SEE). It notes that sales of pharmaceuticals in the SEE region are influenced by generic drugs. It claims that there is a growth in the pharmaceutical market in Bulgaria in terms of value. It also reveals that Serbian pharmaceutical sales reach to 67.1 billion dinars.


Related Articles

  • The Changing Fortunes of APIs. van Arnum, Patricia // Pharmaceutical Technology;Jan2007, Vol. 31 Issue 1, p52 

    The article reports on the expected growth of the global pharmaceutical market particularly the biologics, generic drugs and specialty-initiated drugs. It has been mentioned that this sales forecasting caters finished pharmaceuticals that are reflected in the global market for active...

  • Best may be yet to come for generic drug makers. Kirsche, Michelle L. // Drug Store News;2/14/2005, Vol. 27 Issue 2, p28 

    Reports on the research-and-development pipeline of drug makers in the U.S. Sales of generic companies; Factors contributing to the performance of drug makers; Development of generic pipeline.

  • GPhA bullish on generic industry's future. Cohen, Harold E. // Drug Topics;5/7/2001, Vol. 145 Issue 9, p64 

    Provides information on the Generic Pharmaceutical Association (GPhA), a unification of the generic industry in the United States. Significance of the formation of a united front for the generic industry; Goals of the association; Strategy of pharmacy benefit managers.

  • Is the Generics Industry Ready for Multi-Source Biologics? Challener, Cynthia // Chemical Market Reporter;04/23/2001, Vol. 259 Issue 17, p14 

    Deals with the generic biologic industry. Estimated growth of the biopharmaceutical generics market; Details on the acquisition of Indiana Protein Technologies by Ivax Corp.; European firms preparing to participate in the marketing and sales of generic biopharmaceuticals; Risks faced by a...

  • The International Pharmaceutical Market as a Source of Low-Cost Prescription Drugs for U.S. Patients. Kesselheim, Aaron S.; Choudhry, Niteesh K. // Annals of Internal Medicine;4/15/2008, Vol. 148 Issue 8, p614 

    In response to increasing prescription drug costs, more U.S. patients and policymakers are importing less-expensive pharmaceutical products from other countries. Large-scale prescription drug importation is currently illegal, but the U.S. Food and Drug Administration permits individuals to bring...

  • Antihypertensives: Generics striking at heart of the market.  // PharmaWatch: Monthly Review;Jan2007, Vol. 6 Issue 1, p13 

    The article focuses on the declining growth rate of the antihypertensive drug market in the U.S. which has been attributed to the penetration of generic drugs. It is cited that the slow growth rate does not manifest a stationary market, but a battle between generic drugs and branded ones....

  • AmerisourceBergen's focus is always on the customer.  // Chain Drug Review;7/16/2012, Vol. 34 Issue 12, p35 

    The article focuses on AmerisourceBergen Corp., which has witnessed development in the areas significant for the future of pharmacy, generic drugs, and the needs of customers and patients. AmerisourceBergen's PRxO Generics Solutions initiative and other programs have been designed to enable...

  • Apotex launches first generic version of Paxil.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p10 

    Reports on the launch of the first generic version of GlaxoSmithKline's top-selling antidepressant Paxil in the U.S. by Apotex Corp. Challenges faced by Apotex in the development of the generic version of Paxil; Details of the manufacturing process of the generic drug; Capability of the company...

  • Poor world health and rich world wealth. Taylor, David // BMJ: British Medical Journal (International Edition);03/17/2001, Vol. 322 Issue 7287, p629 

    Editorial. Discusses the use of services provided companies in an attempt to solve the health problems of developing countries. Accusations made by Oxfam and allied aid organizations against the international pharmaceutical industry of denying the world's poor access to essential medicines and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics